Toripalimab-tpzi

(Loqtorzi®)

Loqtorzi®

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormInjection (intravenous; 240 mg/6 mL [40 mg/mL] solution in a single-dose vial)
Drug ClassProgrammed death receptor-1 (PD-1) blocking antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated, in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC).
  • Indicated as single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Toripalimab-tpzi (Loqtorzi) is recommended for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), in combination with cisplatin and gemcitabine. It is also utilized as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC who have disease progression on or after platinum-containing chemotherapy.
  • The study compared different immune checkpoint inhibitors combined with chemotherapy as first-line treatments for recurrent or metastatic NPC.
  • In terms of efficacy, Toripalimab plus gemcitabine-cisplatin demonstrated a significant improvement in overall survival over placebo plus GP, indicating better outcomes for individuals treated with this combination. Nonetheless, Tislelizumab provided the best Progression-Free Survival benefit and objective response rate compared to placebo plus GP.
  • Despite its effectiveness in improving overall survival rates among individuals with NPC, Toripalimab has been associated with more safety concerns than Tislelizumab, considering adverse events of grade ≥3, treatment-related adverse events of grade ≥3, serious adverse events (SAEs), treatment-related SAEs, and discontinuations due to these effects.
  • While both drugs are effective in treating NPCs according to their indications, considerations including previous treatments and specific patient subgroups need to be taken into account during personalized planning, as these factors may influence the choice between Toripalimab and Tislelizumab based on their balance of efficacy and safety profiles respectively.
  • Toripalimab might be deemed a preferable option for some due to its promising efficacy, despite the considerations regarding its safety profile.

Product Monograph / Prescribing Information

Document TitleYearSource
Loqtorzi (toripalimab-tpzi) Prescribing Information2023Coherus BioSciences

Systematic Reviews / Meta-Analyses